Ra Medical Systems Inc (RMED)

[TradingBabyishere]

Not with burning money like they have and doing additional funding rounds.

[SniperStocks]

by the end of the year this will be $1.50-$2.50 organically like it was before covid prices

[TradingBabyishere]

They have to execute one by the end of the year in order to stay listed because they currently don’t meet the PPS minimum.

[John_Langston]

Amen

[starkd748]

That's when trading acumen comes into play....

[John_Langston]

No time soon

[John_Langston]

People got upset because the numbers didn’t meet expected numbers even though they beat last quarter’s numbers. LOL

[John_Langston]

They will be more worthless than they already are on 11/4.

[tmeier]

Any threat of reverse split?

[trickledownfacists]

$41M cash
$10M market cap.

No brainer

[420man]

Many are watching the posts here and can decipher whom the little bitch is... No one likes a pompous dick!

[starkd748]

Buy covi19 stocks lol

[420man]

Pride's a bitch..see ya around

[starkd748]

Dude try at least 20 ...Any penny pharma related to covid19 has ran...This is like weed in 2012....Lol where have you been...I had this on my list to run but then they came out with that stupid pr about not getting into the covid19 space so I bailed...I just checked back in because I got an alerted on the share price ...I've taken this off my watchlist...

[John_Langston]

I didn’t say money can’t be made on one out of a hundred.

[starkd748]

None of mine have gone down lol....Covid19 pennies easy money...

[John_Langston]

I don’t buy stinky pinkies much less at 23 cents.

[starkd748]

Buy some segn you will get your money back

[John_Langston]

It may

[starkd748]

Gl this might hit teens lol

[John_Langston]

At a 30 cent average. LOL LOL LOL

[420man]

I will remember to antagonize you when your trade moved against you in the future.

[420man]

Went against my judgement. Just happy to exit with small profit. These POS's new the #'s. Life trading beaten down penny stocks...sometimes ya loose, sometimes ya break even, and sometimes ya win.

[420man]

Yup..moving on regardless of what the schisters do with the PPS. Someone need to investigate how they can have the earnings estimate changed just 2 days prior to ER. Will it happen...doubtful.

[starkd748]

Lol ouch

[starkd748]

Lol I told you guys this was a bottomless pit I left when they could get the temperature devices ready for covid19....A big Epic Fail

[Werbe]

??? This has been ongoing, this info was in last Q. I am not worried about other people, just what is in front of myself.

[Werbe]

I saw all social media pushing Earnings call. I checked last few earnings, same thing each time. Consensus was way better each time, even the actual yet the PPS would fall dramatically. Numbers do not show what they try to portray. Add in the court info, which I was hoping would get better with new Q. More detailed this time, not good that costs keep going up. Means actual grilling happening, not past tense.

[John_Langston]

It happens every time powerful people lose or make a lot of money on the market.

Look at KODK

[420man]

Agreed, but I really thought the earning this qtr. was going to be the turning point. Sadly, I was mistaken. Bet they try to fabricate a run at some point...or they just wash, rinse, and repeat. Just look at the SP over the past 3 years!

[Werbe]

Government Investigations

As previously announced in the Form 8-K filed on August 12, 2019, the Audit Committee of Ra Medical’s Board of Directors (the “Audit Committee”) conducted an investigation of certain allegations raised by a former employee. The Company announced the Audit Committee’s findings in the Form 8-K filed on October 31, 2019. The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not. The Audit Committee, in reviewing the allegations, identified certain behavior inconsistent with the Company’s Code of Ethics and Conduct and related policies.

As also previously announced, the Company voluntarily contacted the Securities and Exchange Commission’s (the “SEC”) Enforcement Division regarding the Audit Committee’s investigation. On November 13, 2019, the SEC notified the Company that it is conducting an investigation. The Company has been, and intends to continue, cooperating with the SEC in this active and ongoing investigation. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome.

16



In October 2019, the U.S. Department of Justice, or DOJ, served the Company with a Civil Investigative Demand (“CID”) seeking information with respect to a False Claims Act investigation concerning whether the Company fraudulently obtained 510(k) marketing clearance for the Company’s devices marketed under the trade name DABRA, whether the Company marketed and promoted DABRA devices for unapproved uses that were not covered by federal healthcare programs, and whether the Company paid improper remuneration to physicians and other healthcare providers in violation of the Anti-Kickback Statute, 42 U.S.C. §1320a-7b. The Company believes as many as 13 states are participating in the DOJ’s False Claims Act investigation. In response to the DOJ’s CID, the Company reviewed the facts and circumstances of the clinical study used to support its 510(k) marketing clearance and has now completed such review. Following this review, the Company believes there is (i) adequate evidence to support the safety and efficacy reported in the study submitted with the 510(k) application, and (ii) no observations that would have a major impact on the reported results of the study. The Company has been, and intends to continue, cooperating with the DOJ in its active and ongoing investigation. The Company is unable to predict the ultimate outcome and has accrued $2.5 million at June 30, 2020 related to this contingency. It is reasonably possible that the estimated amount will change.

On November 21, 2019, the Company became aware that the Criminal Division, Fraud Section of the U.S. Department of Justice has an open investigation related to the Company. At this time, it is unclear if the Company is a target in this investigation. The Company has been, and intends to continue, cooperating with the DOJ in its active and ongoing investigation. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome

[John_Langston]

That’s common with a stock that’s beat down this bad.

[Werbe]

Im under the impression now the crew that run this ticker are a bunch of shysters. Small inside buys, everything shaped to give the impression of something here. Id advise everyone to read NOTE 13 in the Q.

Government Investigations

As previously announced in the Form 8-K filed on August 12, 2019, the Audit Committee of Ra Medical’s Board of Directors (the “Audit Committee”) conducted an investigation of certain allegations raised by a former employee. The Company announced the Audit Committee’s findings in the Form 8-K filed on October 31, 2019. The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not. The Audit Committee, in reviewing the allegations, identified certain behavior inconsistent with the Company’s Code of Ethics and Conduct and related policies.

As also previously announced, the Company voluntarily contacted the Securities and Exchange Commission’s (the “SEC”) Enforcement Division regarding the Audit Committee’s investigation. On November 13, 2019, the SEC notified the Company that it is conducting an investigation. The Company has been, and intends to continue, cooperating with the SEC in this active and ongoing investigation. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome.

16



In October 2019, the U.S. Department of Justice, or DOJ, served the Company with a Civil Investigative Demand (“CID”) seeking information with respect to a False Claims Act investigation concerning whether the Company fraudulently obtained 510(k) marketing clearance for the Company’s devices marketed under the trade name DABRA, whether the Company marketed and promoted DABRA devices for unapproved uses that were not covered by federal healthcare programs, and whether the Company paid improper remuneration to physicians and other healthcare providers in violation of the Anti-Kickback Statute, 42 U.S.C. §1320a-7b. The Company believes as many as 13 states are participating in the DOJ’s False Claims Act investigation. In response to the DOJ’s CID, the Company reviewed the facts and circumstances of the clinical study used to support its 510(k) marketing clearance and has now completed such review. Following this review, the Company believes there is (i) adequate evidence to support the safety and efficacy reported in the study submitted with the 510(k) application, and (ii) no observations that would have a major impact on the reported results of the study. The Company has been, and intends to continue, cooperating with the DOJ in its active and ongoing investigation. The Company is unable to predict the ultimate outcome and has accrued $2.5 million at June 30, 2020 related to this contingency. It is reasonably possible that the estimated amount will change.

On November 21, 2019, the Company became aware that the Criminal Division, Fraud Section of the U.S. Department of Justice has an open investigation related to the Company. At this time, it is unclear if the Company is a target in this investigation. The Company has been, and intends to continue, cooperating with the DOJ in its active and ongoing investigation. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome

[ClayTrader]

* * $RMED Video Chart 08-11-2020 * *

Link to Video - click here to watch the technical chart video

[420man]

Earnings estimate was .225.... They came in @-.43! That's horrible! Why was the estimate changed from .34 to .225 a couple days ago? Hmmmm. 52 wk low is .276. This is going BK or RS---they had their chance!

[John_Langston]

What a great day, I now have 95,000 shares.

Booyah

[trickledownfacists]

Correction Ra Medical reported cash and cash equivalents of $29.4 million as of June 30, 2020, this doesn't include the 12 million last week in the 3rd quarter it added

$41M cash, $10M market cap

[420man]

NAZ not NYSE. Peeps that picked up .30 and under will now flip. It's over unless they have some type of good news planned ahead. Out with small profit. GL

[trickledownfacists]

This article is wrong. It's 10 days over $1

[420man]

https://www.massdevice.com/ra-medical-threatened-with-stock-exchange-delisting/

[trickledownfacists]

They have until December and can apply for a 6 month extension. Also it's ten day.

You obviously don't know what you are talking about.

[420man]

Peeps got word of earnings @ 2:30. They have to have this above $1 for 30 days or delisting will become effective. So SAD! GL

Now comes the CC gibberish.

[SniperStocks]

Im long here, I believe in the FDA approved products, Patents, and direction, FDA trials underway, I know will be back to the book value

[trickledownfacists]

$30M cash and a $9M market cap

[420man]

DISGUSTING!

[trickledownfacists]

Added.

[420man]

I'm expecting a big run.. JMO

[TradingBabyishere]

I dropped half my shares today but with this dip I’m all back in. I expect earnings to be close enough to provide a boost in the PPS.

New management is all about cutting cost so this is why we expect these guys to go in the green sometime in Q3 to Q4.

[420man]

Back filled the stretch from .31 to .41 with those looking for good earnings results. JMO

[TradingBabyishere]

She’s kicking like a mule.